Read our Recent Headlines


March 24 Biotech Update

Do we have AHCA fatigue yet? It could end today if the House votes no but a yes vote likely means another couple months of debate as it moves to.

March 22 Biotech Update

We finally had a 1%+ down day in the market, so we can finally stop seeing on the tweets about how long it has been since a 1% sell off..

March 21 Biotech Update

While we are still seeing the residual impact of the PCSK9 news and events, I want to step back from that news and focus on some other companies/areas. Clearly it.

March 20 ESPR Update

A quick note on ESPR as I somehow missed the FDA news this morning that a couple of you kindly pointed out. This makes the move much more reasonable than.

March 20 Biotech Update

Another week and another attempt at the 300 level on the IBB and another week with no real M&A. We are still dealing with the aftermath of the AMGN data.

March 17 Biotech Update

Well, this is not going to be a good day for the sector and that wall at 300 in the IBB is likely safe for now. The key culprit is.

March 15 Biotech Update

The PARP wars have ramped up with the AZN data. This was important data for the PARP wars but sort of important for the sector more broadly as this is.

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!